Pimozide-d5 N-Oxide

Pimozide-d5 N-Oxide

• CAS Number: 1794795-40-6
• UNSPSC Description: Pimozide-d5 N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2].
• Target Antigen: Adrenergic Receptor; Dopamine Receptor; Isotope-Labeled Compounds; STAT
• Type: Isotope-Labeled Compounds
• Related Pathways: GPCR/G Protein;JAK/STAT Signaling;Neuronal Signaling;Others;Stem Cell/Wnt
• Field of Research: Cancer; Neurological Disease; Endocrinology
• Solubility: 10 mM in DMSO
• Smiles: O=C1N(C=2C(N1)=CC=CC2)C3(C(CN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)(=O)CC3([2H])[2H])([2H])[2H])[2H]
• Molecular Weight: 482.58
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256(2):141-7.|[3]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9(8):3853-3866. eCollection 2017.|[4]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12): 3421-3429.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported